The Food and Drug Administration has approved 22 new drugs so far in 2017, with a handful of regulatory decisions scheduled for this month, according to Zacks Investment Research.
Here are four companies awaiting regulatory decisions in July, as listed by Zacks.
- Puma Biotechnology seeks FDA approval for neratinib — a follow-up treatment for a form of early stage breast cancer. The drug company expects a response from the FDA by the end of the month.
- Ocular Therapeutix's drug Dextenza is a treatment for eye pain following ophthalmic surgery. The company expects a response from the FDA July 19.
- Eagle Pharmaceuticals expects to hear from the FDA on July 23 regarding the review of its external heat stroke treatment Ryanodex.
- Amgen and UCB will learn if their osteoporosis drug Evenity earns FDA approval July 19.
More articles on supply chain:
6 drugmakers in the headlines
10 most-read supply chain stories in June
Teens have limited access to emergency contraception: 4 study findings